Novocure Ltd (NASDAQ:NVCR) CFO Wilhelmus Cm Groenhuysen sold 31,132 shares of the stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $21.02, for a total transaction of $654,394.64. Following the completion of the sale, the chief financial officer now owns 240,210 shares in the company, valued at $5,049,214.20. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

Wilhelmus Cm Groenhuysen also recently made the following trade(s):

  • On Thursday, January 4th, Wilhelmus Cm Groenhuysen sold 28,868 shares of Novocure stock. The shares were sold at an average price of $21.03, for a total transaction of $607,094.04.

Shares of Novocure Ltd (NVCR) traded up $1.23 during mid-day trading on Thursday, reaching $22.73. 1,191,661 shares of the company’s stock traded hands, compared to its average volume of 632,571. The company has a quick ratio of 5.30, a current ratio of 5.90 and a debt-to-equity ratio of 0.83. The firm has a market cap of $2,020.00 and a P/E ratio of -27.38. Novocure Ltd has a 52-week low of $6.00 and a 52-week high of $22.30.

Novocure (NASDAQ:NVCR) last announced its earnings results on Thursday, October 26th. The medical equipment provider reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.07. The firm had revenue of $50.10 million for the quarter, compared to the consensus estimate of $43.45 million. Novocure had a negative net margin of 47.45% and a negative return on equity of 57.68%. The business’s quarterly revenue was up 130.9% on a year-over-year basis. During the same period last year, the company posted ($0.39) EPS. sell-side analysts forecast that Novocure Ltd will post -0.65 earnings per share for the current year.

A number of analysts recently weighed in on NVCR shares. Wedbush reiterated an “outperform” rating and issued a $25.00 price target (down from $29.00) on shares of Novocure in a research report on Friday, October 27th. Zacks Investment Research upgraded shares of Novocure from a “hold” rating to a “buy” rating and set a $22.00 price target on the stock in a research report on Tuesday, October 31st. JPMorgan Chase & Co. reiterated a “buy” rating on shares of Novocure in a research report on Monday, November 20th. Mizuho reiterated a “buy” rating and issued a $25.00 price target on shares of Novocure in a research report on Friday, December 1st. Finally, ValuEngine upgraded shares of Novocure from a “sell” rating to a “hold” rating in a research report on Sunday, December 31st. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Novocure has a consensus rating of “Buy” and an average price target of $21.13.

Hedge funds have recently made changes to their positions in the business. Crow Point Partners LLC acquired a new stake in Novocure during the 4th quarter worth approximately $120,000. BNP Paribas Arbitrage SA raised its holdings in Novocure by 792.5% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 7,229 shares of the medical equipment provider’s stock worth $125,000 after buying an additional 6,419 shares during the period. Trexquant Investment LP acquired a new stake in Novocure during the 3rd quarter worth approximately $212,000. Legal & General Group Plc raised its holdings in Novocure by 8.5% during the 2nd quarter. Legal & General Group Plc now owns 13,866 shares of the medical equipment provider’s stock worth $238,000 after buying an additional 1,092 shares during the period. Finally, TIAA FSB acquired a new stake in Novocure during the 2nd quarter worth approximately $238,000. Hedge funds and other institutional investors own 41.53% of the company’s stock.

WARNING: This article was published by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of United States & international copyright legislation. The original version of this article can be read at https://www.watchlistnews.com/insider-selling-novocure-ltd-nvcr-cfo-sells-31132-shares-of-stock/1802925.html.

About Novocure

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.

Insider Buying and Selling by Quarter for Novocure (NASDAQ:NVCR)

Receive News & Ratings for Novocure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novocure and related companies with MarketBeat.com's FREE daily email newsletter.